Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINITIVE: Nelitolimod in Colorectal Liver Metastases
NCT07172282Phase 1Recruiting
- Sponsor
- Northwell Health
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nelitolimod in colorectal cancer (CRC), sponsored by Northwell Health. Primary endpoint: Feasibility of neoadjuvant treatment with Nelitolimod delivered via PEDD at 24 months. Started Nov 2025; status: recruiting.
02
Drugs
nelitolimod
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07172282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172282.